ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
International Stem Cell CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026
- Market cap
- $2.27M
- P/E (TTM)
- –
- Dividend yield
- –
International Stem Cell statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Market Cap | $2.27M | $164.85M |
| Enterprise Value | $1.18M | $87.06M |
| PS Ratio | 0.24 | 3.60 |
| P/FCF Ratio | 6.80 | 17.44 |
| P/OCF Ratio | 6.14 | 13.32 |
Enterprise value
| Measure | International Stem Cell | Industry median |
|---|---|---|
| EV / Sales | 0.12 | 2.43 |
| EV / FCF | 3.53 | 20.97 |
Income (trailing twelve months)
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Revenue | $9.51M | $57.94M |
| Gross Profit | $5.23M | $90.47M |
| Operating Income | -$444.00K | -$21.44M |
| Net Income | -$582.00K | -$22.46M |
| EBITDA | -$272.00K | -$16.91M |
| EPS (Diluted) | -$0.08 | -$0.83 |
Margins
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Gross Margin | 55.0% | 52.3% |
| Operating Margin | -4.67% | -44.5% |
| Profit Margin | -6.12% | -39.2% |
| EBITDA Margin | -2.86% | -31.3% |
| FCF Margin | 3.50% | -8.85% |
Returns
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Return on Assets (ROA) | -11.0% | -41.0% |
| Return on Capital Employed (ROCE) | -616.7% | -37.8% |
Growth
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.40% | 6.01% |
| FCF Growth (YoY) | 851.4% | 2.34% |
| Revenue Growth (3Y CAGR) | 3.62% | 2.25% |
| Revenue Growth (5Y CAGR) | 5.01% | 6.42% |
Balance sheet
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.09M | $62.42M |
| Net Cash (Debt) | $1.09M | $15.68M |
| Net Cash Per Share | $0.14 | $0.66 |
| Equity (Book Value) | -$4.23M | $48.79M |
| Book Value Per Share | -$0.53 | $1.36 |
| Tangible Book Value | -$4.74M | $23.06M |
| Working Capital | -$1.06M | $75.77M |
Financial position
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Current Ratio | 0.79 | 3.30 |
| Quick Ratio | 0.41 | 2.39 |
| Interest Coverage | -3.15 | -7.12 |
Cash flow (trailing twelve months)
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Operating Cash Flow | $369.00K | -$12.35M |
| Capital Expenditures | -$36.00K | -$1.06M |
| Free Cash Flow | $333.00K | -$20.28M |
| FCF Per Share | $0.04 | -$0.42 |
Efficiency
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Asset Turnover | 1.79 | 0.38 |
| Inventory Turnover | 2.65 | 2.67 |
| Revenue Per Employee | $288.30K | $398.96K |
| Profits Per Employee | -$17.64K | -$703.34K |
| Employee Count | 33 | 74 |
Dividends and yields
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Earnings Yield | -25.7% | -22.7% |
| FCF Yield | 14.7% | -9.07% |
Shares
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Shares Outstanding | 8,004,390 | 58,179,650 |
| Shares Change (YoY) | 0.51% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 7,967,940 | 49,173,100 |
| Shares Held by Insiders | 0.46% | 11.6% |
Scores
| Measure | International Stem Cell | Industry median |
|---|---|---|
| Altman Z-Score | -29.23 | -0.24 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -3.20 | -2.62 |
Calculated by StockData from International Stem Cell's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.